---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-014403"
form_type: "8-K"
ticker: null
cik: "0001850838"
company_name: "Omega Therapeutics, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:28:28.509705+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Two Omega directors resign; Jeffrey Varsalone appointed to board

## Summary
- Ravi Mehrotra and Robert Rosiello resigned from the board effective January 22, 2025.
- Board appointed Jeffrey Varsalone as Class I director effective January 24, 2025; monthly cash fee of $30,000.
- Richard Kender moved from Class III to Class II director to rebalance board classes.
- Board now consists of two directors per class (I, II, III).

## SEC filing metadata
- accession: 0001193125-25-014403
- form_type: 8-K
- cik: 0001850838
- company_name: Omega Therapeutics, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/d893135d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-014403
- JSON: https://secwatch.observer/filing/0001193125-25-014403.json
- Plain text: https://secwatch.observer/filing/0001193125-25-014403.txt

## Key facts
- Executive change
  Jeffrey T. Varsalone was appointed as Class I Director at Omega Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On January 24, 2025, the Board appointed Jeffrey T. Varsalone as a Class I director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm
- Executive change
  Robert L. Rosiello resigned as Class I Director at Omega Therapeutics, Inc..
  - Action: resigned
  - Role: Class I Director
  source text: On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm
- Executive change
  Ravi Mehrotra resigned as Class I Director at Omega Therapeutics, Inc..
  - Action: resigned
  - Role: Class I Director
  source text: On January 22, 2025, Ravi Mehrotra, Ph.D. and Robert L. Rosiello each submitted their resignation as a member of the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850838/000119312525014403/0001193125-25-014403-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.